P863: AN OPEN-LABEL PHASE I/IIA STUDY TO EVALUATE THE SAFETY AND EFFICACY OF CCS1477 AS MONOTHERAPY AND IN COMBINATION WITH POMALIDOMIDE/DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA

• Emma Searle,
• Jim Cavet,
• Steven Knapper,
• Ceri Bygrave,
• Victoria Campbell,
• Dima El-Sharkawi,
• Charlotte Pawlyn,
• Maria Creignou,
• Harriet S. Walter,
• David Valcarcel,
• Marta Hidalgo,
• Tomasz Knurowski,
• Karen Clegg,
• Neil Pegg,
• Will West,
• Debbie Haynes,
• Kris Frese,
• Tim C. P. Somervaille

Affiliations

Emma Searle

1 The Christie NHS Foundation Trust, Manchester, United Kingdom

Jim Cavet

1 The Christie NHS Foundation Trust, Manchester, United Kingdom

Steven Knapper

3 Cardiff University, Cardiff, United Kingdom

Ceri Bygrave

4 University Hospital Wales, Cardiff, United Kingdom

Victoria Campbell

5 Western General Hospital, Edinburgh, United Kingdom

Dima El-Sharkawi

6 The Royal Marsden NHS Foundation Trust, London, United Kingdom

Charlotte Pawlyn

6 The Royal Marsden NHS Foundation Trust, London, United Kingdom

Maria Creignou

8 Karolinska University Hospital, Stockholm, Sweden

Harriet S. Walter

9 University Hospitals Leicester, Leicester, United Kingdom

David Valcarcel

11 Vall d’Hebron Institute of Oncology, Barcelona, Spain

Marta Hidalgo

11 Vall d’Hebron Institute of Oncology, Barcelona, Spain

Tomasz Knurowski

12 CellCentric Ltd, Cambridge, United Kingdom

Karen Clegg

12 CellCentric Ltd, Cambridge, United Kingdom

Neil Pegg

12 CellCentric Ltd, Cambridge, United Kingdom

Will West

12 CellCentric Ltd, Cambridge, United Kingdom

Debbie Haynes

12 CellCentric Ltd, Cambridge, United Kingdom

Kris Frese

12 CellCentric Ltd, Cambridge, United Kingdom

Tim C. P. Somervaille

1 The Christie NHS Foundation Trust, Manchester, United Kingdom